CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a worldwide biotechnology firm targeted on growing and commercializing progressive medicines, right now introduced that Julia Wang has been appointed as Chief Monetary Officer, efficient June 30, 2021. Ms. Wang will succeed Howard Liang, Ph.D., who beforehand introduced his intention to retire from BeiGene and can keep on by way of June 30 to make sure an orderly transition.
Ms. Wang has in depth international finance expertise throughout the biotech, pharmaceutical, medical system, diagnostic, and shopper merchandise industries. She joined BeiGene in June 2020 as Senior Vice President, Enterprise Optimization and Deputy CFO, primarily based within the Firm’s Cambridge, MA workplace, and has been instrumental in driving worth creation by way of partnering throughout the group and optimizing useful resource allocation whereas elevating the management of the Finance operate. In reference to the CFO transition, Angus Grant, Ph.D., Chief Enterprise Govt, will oversee the Firm’s technique groups.
“Julia has had an essential impression and been an integral member of our govt staff since becoming a member of BeiGene almost a 12 months in the past. We’re lucky to have her deep experience in main monetary operations as we turn into a bigger group with hundreds of colleagues and in depth operations all over the world,” commented John V. Oyler, Co-Founder, Chief Govt Officer, and Chairman of BeiGene. “We’re grateful to have had Howard’s service since 2015, as a devoted, insightful chief and pal. We want him the perfect and thank him for his many contributions, together with the continuing transition of his duties.”
“I’m humbled by the chance to function CFO of BeiGene, as we glance to remodel the biotechnology business by creating impactful medicines that will probably be inexpensive and accessible to much more sufferers all over the world,” commented Ms. Wang. “Our dedication to serve sufferers resonates all through the corporate within the work we do every day. I purpose to construct on the stable basis that Howard has established for BeiGene as a dual-listed, commercial-stage development firm, with sources that enable us to proceed to put money into our enterprise as we endeavor to perform our crucial mission.”
Previous to becoming a member of BeiGene, Ms. Wang served as Senior Vice President, International Enterprise Finance and Company Planning at Alexion Prescription drugs. Previous to that she held management positions at Quest Diagnostics, together with Vice President of U.S. Regional Finance and Enterprise Industrial, and Vice President of Finance, Worth Creation. Earlier than Quest, Ms. Wang held senior management roles at Johnson & Johnson (J&J) as CFO of assorted working companies, together with Xian-Janssen, J&J’s pharmaceutical enterprise in China. Beforehand, she additionally led finance initiatives at PepsiCo.
Ms. Wang earned her MBA from Fuqua Faculty of Enterprise at Duke College and her BA in British Language and Literature from Shandong Regular College.
BeiGene is a worldwide, commercial-stage biotechnology firm targeted on discovering, growing, manufacturing, and commercializing progressive medicines to enhance therapy outcomes and entry for sufferers worldwide. Our 5,400+ workers all over the world are dedicated to expediting the event of a various pipeline of novel therapeutics. We presently market two internally found oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in america and China, and anti-PD-1 antibody tislelizumab in China. We additionally market or plan to market further oncology merchandise in China licensed from Amgen Inc.; Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) firm; and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop, manufacture and commercialize tislelizumab in North America, Europe, and Japan. To be taught extra about BeiGene, please go to www.beigene.com and observe us on Twitter at @BeiGeneUSA.
This press launch accommodates forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995 and different federal securities legal guidelines, together with statements concerning BeiGene’s capability and drive to carry progressive medicines extra affordably to sufferers all over the world and have a sustained impression the biotechnology business. Precise outcomes might differ materially from these indicated within the forward-looking statements because of numerous essential elements, together with BeiGene’s capability to display the efficacy and security of its drug candidates; the scientific outcomes for its drug candidates, which can not assist additional improvement or advertising approval; actions of regulatory companies, which can have an effect on the initiation, timing and progress of scientific trials and advertising approval; BeiGene’s capability to realize industrial success for its marketed medicines and drug candidates, if accepted; BeiGene’s capability to acquire and keep safety of mental property for its medicines and expertise; BeiGene’s reliance on third events to conduct drug improvement, manufacturing and different companies; BeiGene’s restricted expertise in acquiring regulatory approvals and commercializing pharmaceutical merchandise and its capability to acquire further funding for operations and to finish the event of its drug candidates and obtain and keep profitability; the impression of the COVID-19 pandemic on the BeiGene’s scientific improvement, regulatory, industrial, and different operations, in addition to these dangers extra totally mentioned within the part entitled “Danger Elements” in BeiGene’s most up-to-date annual report on Kind 10-Okay in addition to discussions of potential dangers, uncertainties, and different essential elements in BeiGene’s subsequent filings with the U.S. Securities and Change Fee. All data on this press launch is as of the date of this press launch, and BeiGene undertakes no responsibility to replace such data until required by legislation.